Safety Study of Tasfygo Tablet 35 mg in Patients With Unresectable Biliary Tract Cancer and FGFR2 Fusion Gene Who Have Progressed After Chemotherapy

What this Trial Is About

Researchers are evaluating the safety of Tasfygo in patients with unresectable biliary tract cancer who have a specific FGFR2 fusion gene and whose cancer has progressed after chemotherapy. This observational study aims to monitor how participants respond to Tasfygo in a real-world setting without altering their standard care. Participants will receive Tasfygo tablets at a dose of 35 mg as part of their normal treatment routine. Since this is a non-interventional study, researchers will not assign treatments but will observe and collect data on participants who are already prescribed Tasfygo. The study will follow participants for up to one year to assess safety and response. During the study, researchers will track the number of participants experiencing adverse drug reactions and assess the best overall response based on physicians evaluations. Data will be collected through regular clinical assessments over the course of the year. Participants will continue their usual care alongside study observations, and the total participation time spans up to one year.

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy